Description: Hugel, Inc. operates as a biopharmaceutical company in South Korea and internationally. It offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. The company also provides hyaluronic acid filler under the Dermalax, Hyalsense, Revigance, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
Home Page: www.hugel.co.kr
61-20, Sinbuk-ro
Chuncheon-si,
24206
South Korea
Phone:
82 3 3255 3882
Officers
| Name | Title |
|---|---|
| Mr. Ji-hoon Sohn | CEO & Exec. Director |
| J. T. Kim | MD & CFO |
| Mr. Chang-Jin Lee | Sr. MD & Head of Devel. Division |
| Seonho Han | VP and Chief Sales & Marketing Officer |
| Mr. Soon-Woo Kwon | VP & Chief Production Officer |
| Jennifer Rho | MD & Chief Strategy Officer |
| Minjong Kang | MD & Head of Marketing |
| Jihye Song | MD & Head of Cosmetics |
| Young Mahn Yoo | MD & Chief Production Officer |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 2.3077 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 479 |